ProQR Announces Results for the Third Quarter of 2015 and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials

LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA), today announced results for the third quarter of 2015 and a delay in top-line data readout for the ongoing clinical studies in CF. Data is now expected to be released in mid to late 2016.

“During the third quarter we announced we started our second clinical study of QR-010 (PQ-010-002) in patients with CF and the ∆F508 mutation, that is running in parallel with the Phase 1b (PQ-010-001) study. While patient enrollment is going well in both studies, the ramp up of enrollment is slower than expected. We attribute this to very robust but stringent protocols and the large number of competing studies," said Daniel de Boer, Chief Executive Officer of ProQR. “Our teams have taken a number of steps to accelerate enrollment without compromising on quality. The results from both studies together will give us a strong indication of the potential of QR-010 to make a difference in the lives of patients with CF.”

Financial Highlights

At September 30, 2015, ProQR held cash and cash equivalents of €100.0 million, compared to €106.4 million at June 30, 2015. Net cash used in operating activities during the three month period ended September 30, 2015 was €6.3 million, compared to €4.3 million for the same period last year.

Research and development costs increased to €6.0 million for the quarter ended September 30, 2015 from €2.5 million for the same period in 2014 and comprised of costs of clinical trials, allocated employee costs including share-based payments, the costs of materials and laboratory consumables, license and intellectual property costs and other allocated costs. The increase in expenses was due to clinical development of QR-010 for patients with CF due to the ∆F508 mutation; development activities related to QR-110 for LCA due to the p.Cys998X mutation; and increased investment into our RNA based therapeutics pipeline.

General and administrative costs decreased to €1.5 million for the quarter ended September 30, 2015 from €2.4 million for the same period in 2014, driven by the costs the Company’s IPO on the Nasdaq Global market in September 2014.

Net result for the three month period ended September 30, 2015 was a €6.3 million loss or €0.27 per share, compared to a €3.4 million loss or €0.43 per share for the same period in 2014. For further financial information for the period ending September 30, 2015, please refer to the financial statements appearing at the end of this release.

Corporate Highlights

  • Enrollment has started in study PQ-010-002, a global proof-of-concept nasal potential difference (NPD) study of QR-010. PQ-010-002 is a case-controlled, open label 28-day study to be conducted in approximately 5 specialized centers with planned enrollment of 8 CF patients that are homozygous (carrying two copies) for the DF508 mutation and 8 CF patients that are compound heterozygous (one copy of the ∆F508 plus one other CF disease causing mutation). This second human study in affected patients will evaluate the change in NPD after topical administration of QR-010. QR-010 is a novel investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the ∆F508 mutation.

Subsequent events

  • The company presented an oral presentation and poster with pre-clinical data on the delivery of QR-010 to the CF diseased lung at the North American Cystic Fibrosis Conference (NACFC) [October 8-11 in Phoenix, Arizona]. QR-010 was demonstrated to be stable in sputum collected from CF patients.  QR-010 easily diffuses through CF-like mucus in vitro and in vivo in a clinically relevant timeframe. Solute percentage in the mucus will slow diffusion slightly but it is not a clinically meaningful difference. QR-010 is absorbed systemically after orotracheal administration in normal and betaENaC mice, a mouse model where the lungs have similar mucus and related findings to humans with CF. Quantitative assays showed no difference between normal and betaENaC mice. QR-010 remained stable in mixing studies with three commonly used CF medications: dornase alfa (Pulmozyme®), fluticasone and salbutamol.
  • Update on the Phase 1b (PQ-010-001) and NPD (PQ-010-002) trials: Patient enrollment continues in Europe and North America for QR-010 for patients with CF associated with the ∆F508 mutation.  ProQR is now expecting to release top-line data in mid to late 2016. Patient screening and enrollment is going well, however due to stringent inclusion/exclusion criteria and the recent increase of clinical studies competing for the same patient population, the predicted acceleration of enrollment has not occurred. ProQR is actively implementing recruitment strategies.

About QR-010

QR-010 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by repairing the mRNA defect encoded by the DF508 mutation in the CFTR gene of CF patients. The DF508 mutation is a deletion of three of the coding base pairs, or nucleotides, in the CFTR gene, which results in the production of a misfolded CFTR protein that does not function normally. QR-010 is designed to bind to the defective CFTR mRNA and guide the insertion of the three missing nucleotides, thus repairing the mRNA and subsequently producing wild-type, or normal CFTR protein. QR-010 is designed to be self-administered through a small, handheld aerosol delivery device, or nebulizer, in the form of a mist inhaled into the lungs. We believe this method could allow maximum exposure of QR-010 to the primary target organ, the lung, as well as significant exposure to other affected organs through systemic absorption into the blood. QR-010 has been granted orphan drug designation in the United States and the European Union. The QR-010 project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

FORWARD-LOOKING STATEMENTS  

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-010 and QR-110, statements regarding our ongoing and planned discovery and development of product candidates, statements regarding the expected timing of results from our clinical studies and statements regarding the Horizon 2020 program. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

ProQR Therapeutics N.V.:  Sariette Witte Investor Relations T: +1 213 261 8891  ir@proqr.com

PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position

         
    September 30, 2015   December 31, 2014
    € 1,000   € 1,000
Assets        
Current assets        
Cash and cash equivalents   100,012   112,736
Prepayments and other receivables   1,788   735
Social securities and other taxes   845   426
         
         
Total current assets   102,645   113,897
         
Property, plant and equipment   1,980   1,187
Intangible assets   153   163
         
Total assets   104,778   115,247
         
Liabilities and shareholders' equity        
Current liabilities        
Finance lease liabilities   22   34
Trade payables   98   1,247
Social securities and other taxes   11   341
Pension premiums   198   127
Deferred income   700   --
Other current liabilities   3,784   1,265
         
Total current liabilities   4,813   3,014
         
Finance lease liabilities   -   15
Borrowings   4,334   2,814
         
Total liabilities   9,147   5,843
         
Shareholders' equity        
Shareholders' equity   95,631   109,404
         
Total liabilities and shareholders' equity   104,778   115,247

PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Profit or Loss and OCI (€ in thousands, except share and per share data)

                                 
    Three month period   Nine month period
    ended September 30,   ended September 30,
                                 
      2015       2014       2015       2014  
      € 1,000       € 1,000       € 1,000       € 1,000  
Other income     1,191       --       2,277       4  
                 
Research and development costs     (6,000 )     (2,457 )     (16,907 )     (6,994 )
General and administrative costs     (1,458 )     (2,380 )     (4,838 )     (4,510 )
                 
Total operating costs     (7,458 )     (4,837 )     (21,745 )     (11,504 )
                 
Operating result     (6,267 )     (4,837 )     (19,468 )     (11,500 )
Finance income and expense     (50 )     1,462       4,762       1,410  
                 
Result before corporate income taxes     (6,317 )     (3,375 )     (14,706 )     (10,090 )
Income taxes     --       --       --       --  
                 
Net loss attributable to equity holders of the Company     (6,317 )     (3,375 )     (14,706 )     (10,090 )
Other comprehensive income     --       --       --        --  
                 
Total comprehensive loss (attributable to equity holders of the Company)     (6,317 )     (3,375 )     (14,706 )     (10,090 )
                 
Share information                
Weighted average number of shares outstanding 1     23,345,170       7,916,686       23,342,386       6,952,792  
                                 
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)                                
Basic loss per share 1     (0.27 )     (0.43 )     (0.63 )     (1.45 )
Diluted loss per share 1     (0.27 )     (0.43 )     (0.63 )     (1.45 )
  1. For the periods presented in these financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary shares in 2014 are not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal.

PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Changes in Equity

                         
    Number of shares           Equity        
            Settled        
            Total       Employee        
      Ordinary     Preferred   Share   Share   Benefit   Accumulated   Total
        Capital   Premium   Reserve   Deficit   Equity
              € 1,000       € 1,000     € 1,000     € 1,000       € 1,000  
Balance at January 1, 2014     6,108,152       --       59       3,482     41     (3,671 )     (89 )
Net loss     --       --       --       --     --     (10,090 )      (10,090 ) 
Recognition of share-based payments     --       --       --       --     406     --       406  
Shares issued in the period     9,490,336       8,265,179       880       122,291     --     --       123,171  
Conversion of preferred shares     8,265,179       (8,265,179 )     --       --     --     --       --  
Treasury shares issued     (525,513 )     --       (5 )     (2,191 )   --     --       (2,196 )
                                     
Balance at September 30, 2014     23,338,154       --       934       123,582     447     (13,761 )     111,202  
                                 
Balance at January 1, 2015     23,338,154       --       934       123,581     687     (15,798 )     109,404  
Net loss     --       --       --       --     --     (14,706 )     (14,706 )
Recognition of share-based payments     --       --       --       --     919     --       919  
Share options exercised     7,684       --       0       14     --     --       14  
                                 
Balance at September 30, 2015     23,345,838       --       934       123,595     1,606     (30,504 )     95,631  
                             

PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Cash Flows

         
    Three month period   Nine month period
    ended September 30,   ended September 30,
      2015       2014       2015       2014  
      € 1,000       € 1,000       € 1,000       € 1,000  
Cash flows from operating activities                
Net loss     (6,317 )     (3,375 )     (14,706 )     (10,090 )
Adjustments for:                
— Depreciation     126       26       338       65  
— Share-based compensation     300       178       919       406  
— Financial income and expenses     50       (1,462 )     (4,762 )     (1,410 )
                 
Changes in working capital     (527 )     205       472       1,405  
Cash used in operations     (6,368 )     (4,428 )     (17,739 )     (9,624 )
                 
Corporate income tax paid     --       --       --       --  
Interest received/(paid)     104       129       281       148  
                 
Net cash used in operating activities     (6,264 )     (4,299 )     (17,458 )     (9,476 )
                 
Cash flow from investing activities                
Purchases of property, plant and equipment     (56 )     (344 )     (1,093 )     (594 )
Purchases of intangible assets     --       --       (28 )     --  
                 
Net cash used in investing activities     (56 )     (344 )     (1,121 )     (594 )
                 
Cash flow from financing activities                
Proceeds from issuance of shares, net of transaction costs     --       80,258       --       118,100 1  
Proceeds from exercise of share options     8       --       14       --  
Proceeds from borrowings     --       1       1,254       1,667  
Redemption of financial lease     (7 )     (10 )     (27 )     (27 )
                 
Net cash generated by financing activities     1       80,249       1,241       119,740  
                 
Net increase/(decrease) in cash and cash equivalents     (6,319 )     75,606       (17,338 )     109,670  
                 
Currency effect cash and cash equivalents     (51 )     1,458       4,614       1,458  
Cash and cash equivalents, at beginning of the period     106,382       38,193       112,736       4,129  
                 
Cash and cash equivalents at the end of the period     100,012       115,257       100,012       115,257  
                 

 

  1. Net of non-cash conversion of convertible loan.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 112

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 97

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 202

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 55

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 204

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 97

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 173

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 97

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading

Top 5 Most Recently Viewed Articles

Pivot Point Consulting Triumphs as KLAS Leader for IT Services

Updated Category News Views 146

Pivot Point Consulting Recognized as a Leader in Managed IT Services For three consecutive years, Pivot Point Consulting has earned the prestigious title of #1 Best in KLAS: Managed IT Services. This recognition, based on outstanding client feedback, highlights their ongoing commitment to excellence in the healthcare IT sector. The Significance of KLAS Rankings KLAS...

Continue Reading
Revolutionizing Intelligent Vision: Leopard Imaging's New Offerings

Updated Category News Views 203

Revolutionizing Intelligent Vision Solutions Leopard Imaging Inc., a pioneering company in intelligent vision technology, has unveiled its groundbreaking high-resolution RGB-IR stereo camera series, known as Eagle. This series is powered by two of the most advanced technologies from NVIDIA: Holoscan and Jetson Thor. As a leading innovator in the realm of intelligent...

Continue Reading
Gartner's CEO Eugene Hall Executes Major Stock Sales

Updated Category News Views 320

Eugene Hall's Major Stock Sales at Gartner Gartner Inc. (NYSE: IT) is in the spotlight following a significant stock sale by its Chairman and CEO, Eugene A. Hall. This recent move, detailed in an SEC filing, shows that Hall sold shares worth a considerable total of $17,213,808. Overview of Hall's Stock Transactions Hall's stock sales occurred over several transactions,...

Continue Reading
How Canadian Tariffs Could Impact These 5 Companies

Updated Category News Views 1409

Understanding the Potential Impact of Canadian Tariffs The announcement of possible tariffs on Canadian imports has taken many businesses by surprise, igniting a wave of concern across multiple sectors. Companies are now racing to reassess their strategies as new cost structures could potentially shape their futures. What Does This Mean for U.S. Companies? The initiative...

Continue Reading
Holley Performance Brands Launches Major Stock Offering

Updated Category News Views 309

Holley Performance Brands Unveils Secondary Stock Offering Holley Performance Brands (NYSE: HLLY) has recently made headlines by announcing a secondary offering of its common stock, which aims to raise capital and create further investment opportunities for investors. This move underscores Holley's commitment to enhancing its presence in the automotive performance market....

Continue Reading